Short answer
Vanda Pharmaceuticals Inc. (VNDA) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Quarterly results covered period ended June 30, 2026.
Vanda Pharmaceuticals Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Quarterly results covered period ended June 30, 2026
- Press release furnished as Exhibit 99.1; key financial figures require review of the exhibit
- Earnings call includes pipeline development, regulatory timelines, and commercial potential
- Forward-looking statements carry execution and regulatory approval risks
- Investor focus: U.S. business strength and ability to advance pipeline products
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $50.5M, down 4%; Fanapt sales rose 23% to $36.0M, offset by HETLIOZ decline
- Net loss widened to $62.5M, or $1.04 per share, from $27.2M as R&D and launch spending increased
- Cash $170.0M after a $32.3M quarterly decline; management expects funding through at least 2027
- 2026 revenue guidance reiterated at $240M-$290M, including $10M-$30M from newly launched NEREUS
- BYSANTI launch expected in second half 2026; Quimilza FDA decision targeted December 12, 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vanda Pharmaceuticals Inc. 8-K filings
Get the next VNDA 8-K as it lands
Follow VNDA for push alerts, or ask the research agent what this filing means.